In the context of hematological disorders, such as AML, TGF-β can act both as a tumor suppressor, due to its role in cell proliferation and apoptosis, but also as a tumor promoter because of its effects on migration and downregulation of effective immune responses [106]. The gene discussed is TGFB1; the disease is hematologic disorder.